COVID-19治疗干预措施:一项含荟萃分析和试验序贯分析的活体系统评价(LIVING项目)
该活体系统评价纳入33项随机临床试验共13312例COVID-19患者,评估多种治疗干预的效果。地塞米松可能降低全因死亡率和机械通气需求,瑞德西韦可能减少严重不良事件,但证据确定性低至极低;可排除羟氯喹较标准治疗降低死亡和严重不良事件风险20%或以上的可能性。
要点
- 地塞米松可能降低COVID-19患者全因死亡率(RR 0.83)和机械通气风险(RR 0.77),证据确定性低。
- 瑞德西韦对全因死亡率无显著差异,但可能减少严重不良事件(RR 0.77),证据确定性极低。
- 可排除羟氯喹较标准治疗降低死亡和严重不良事件风险20%或以上的可能性,且增加非严重不良事件风险。
核心结论
- 地塞米松和瑞德西韦可能对COVID-19患者有益,但证据确定性低至极低,需更多试验验证。
- 可排除羟氯喹较标准治疗降低死亡和严重不良事件风险20%或以上的可能性。
- 除此之外,目前尚无证据支持的COVID-19治疗方法。
研究设计与样本
- 活体系统评价,基于PRISMA和Cochrane指南,采用8步流程验证荟萃分析结果的临床意义。
- 纳入33项随机临床试验,共13312例各年龄组COVID-19参与者,检索截至2020年8月7日。
- 计划进行聚合数据荟萃分析、试验序贯分析、网络荟萃分析和个体患者数据荟萃分析。
- 所有纳入试验总体存在高偏倚风险。
主要发现
- 地塞米松对比标准治疗(1项试验,6425例):全因死亡率率比0.83(95%CI 0.75-0.93;p<0.001;低确定性),机械通气风险比0.77(95%CI 0.62-0.95;p=0.021;低确定性)。
- 瑞德西韦对比安慰剂(2项试验):全因死亡率RR 0.74(95%CI 0.40-1.37;p=0.34;I2=58%;极低确定性),非严重不良事件RR 0.94(95%CI 0.80-1.11;p=0.48;I2=29%;低确定性),严重不良事件RR 0.77(95%CI 0.63-0.94;p=0.009;I2=0%;极低确定性)。
- 羟氯喹对比标准治疗(7项试验):全因死亡率RR 1.07(95%CI 0.97-1.19;p=0.17;I2=0%;低确定性),严重不良事件RR 1.07(95%CI 0.96-1.18;p=0.21;I2=0%;低确定性),非严重不良事件RR 2.40(95%CI 2.01-2.87;p<0.00001;I2=90%;极低确定性)。
- 洛匹那韦-利托那韦对比标准治疗(2项试验):严重不良事件RR 0.64(95%CI 0.39-1.04;p=0.07;I2=0%;极低确定性),非严重不良事件RR 1.14(95%CI 0.85-1.53;p=0.38;I2=75%;极低确定性)。
- 恢复期血浆对比标准治疗(2项试验):全因死亡率RR 0.60(95%CI 0.33-1.10;p=0.10;I2=0%;极低确定性)。
关键数值与推荐
- 主要结局为全因死亡率和严重不良事件;次要结局包括入住重症监护、机械通气、肾脏替代治疗、生活质量和非严重不良事件。
- 采用GRADE评估证据确定性。
- 试验序贯分析可排除羟氯喹较标准治疗降低全因死亡率和严重不良事件风险20%或以上的可能性。
临床怎么用
- 地塞米松可考虑用于COVID-19患者,但需认识到证据确定性低。
- 瑞德西韦可能减少严重不良事件,但对死亡率无显著影响,证据确定性极低。
- 不推荐使用羟氯喹治疗COVID-19,因其不能降低死亡和严重不良事件风险且增加非严重不良事件。
局限性
- 当前可用数据匮乏,无法进行其他荟萃分析、网络荟萃分析或个体患者数据荟萃分析。
- 所有纳入试验均存在系统误差和随机误差风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coronavirus disease 2019 (COVID-19) is a rapidly spreading disease that has caused extensive burden to individuals, families, countries, and the world. Effective treatments of COVID-19 are urgently needed. METHODS AND FINDINGS: This is the first edition of a living systematic review of randomized clinical trials comparing the effects of all treatment interventions for participants in all age groups with COVID-19. We planned to conduct aggregate data meta-analyses, trial sequential analyses, network meta-analysis, and individual patient data meta-analyses. Our systematic review is based on Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) and Cochrane guidelines, and our 8-step procedure for better validation of clinical significance of meta-analysis results. We performed both fixed-effect and random-effects meta-analyses. Primary outcomes were all-cause mortality and serious adverse events. Secondary outcomes were admission to intensive care, mechanical ventilation, renal replacement therapy, quality of life, and nonserious adverse events. We used Grading of Recommendations Assessment, Development and Evaluation (GRADE) to assess the certainty of evidence. We searched relevant databases and websites for published and unpublished trials until August 7, 2020. Two reviewers independently extracted data and assessed trial methodology. We included 33 randomized clinical trials enrolling a total of 13,312 participants. All trials were at overall high risk of bias. We identified one trial randomizing 6,425 participants to dexamethasone versus standard care. This trial showed evidence of a beneficial effect of dexamethasone on all-cause mortality (rate ratio 0.83; 95% confidence interval [CI] 0.75-0.93; p < 0.001; low certainty) and on mechanical ventilation (risk ratio [RR] 0.77; 95% CI 0.62-0.95; p = 0.021; low certainty). It was possible to perform meta-analysis of 10 comparisons. Meta-analysis showed no evidence of a difference between remdesivir versus placebo on all-cause mortality (RR 0.74; 95% CI 0.40-1.37; p = 0.34, I2 = 58%; 2 trials; very low certainty) or nonserious adverse events (RR 0.94; 95% CI 0.80-1.11; p = 0.48, I2 = 29%; 2 trials; low certainty). Meta-analysis showed evidence of a beneficial effect of remdesivir versus placebo on serious adverse events (RR 0.77; 95% CI 0.63-0.94; p = 0.009, I2 = 0%; 2 trials; very low certainty) mainly driven by respiratory failure in one trial. Meta-analyses and trial sequential analyses showed that we could exclude the possibility that hydroxychloroquine versus standard care reduced the risk of all-cause mortality (RR 1.07; 95% CI 0.97-1.19; p = 0.17; I2 = 0%; 7 trials; low certainty) and serious adverse events (RR 1.07; 95% CI 0.96-1.18; p = 0.21; I2 = 0%; 7 trials; low certainty) by 20% or more, and meta-analysis showed evidence of a harmful effect on nonserious adverse events (RR 2.40; 95% CI 2.01-2.87; p < 0.00001; I2 = 90%; 6 trials; very low certainty). Meta-analysis showed no evidence of a difference between lopinavir-ritonavir versus standard care on serious adverse events (RR 0.64; 95% CI 0.39-1.04; p = 0.07, I2 = 0%; 2 trials; very low certainty) or nonserious adverse events (RR 1.14; 95% CI 0.85-1.53; p = 0.38, I2 = 75%; 2 trials; very low certainty). Meta-analysis showed no evidence of a difference between convalescent plasma versus standard care on all-cause mortality (RR 0.60; 95% CI 0.33-1.10; p = 0.10, I2 = 0%; 2 trials; very low certainty). Five single trials showed statistically significant results but were underpowered to confirm or reject realistic intervention effects. None of the remaining trials showed evidence of a difference on our predefined outcomes. Because of the lack of relevant data, it was not possible to perform other meta-analyses, network meta-analysis, or individual patient data meta-analyses. The main limitation of this living review is the paucity of data currently available. Furthermore, the included trials were all at risks of systematic errors and random errors. CONCLUSIONS: Our results show that dexamethasone and remdesivir might be beneficial for COVID-19 patients, but the certainty of the evidence was low to very low, so more trials are needed. We can exclude the possibility of hydroxychloroquine versus standard care reducing the risk of death and serious adverse events by 20% or more. Otherwise, no evidence-based treatment for COVID-19 currently exists. This review will continuously inform best practice in treatment and clinical research of COVID-19.
引用
- Juul S, Nielsen EE, Feinberg J, et al. Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project). PLoS Med. 2020. PMID: 32941437. doi:10.1371/journal.pmed.1003293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。